Finding new ways to treat osteoporosis

Blastoff Study

Osteoporosis is a condition where the bones become weak, are described as fragile and can easily break (fracture). When a person has suffered one fracture from a fall of standing height or less (a fragility fracture), the risk of sustaining another fragility fracture is high.

Bisphosphonates are a group of medicines prescribed for people with, or at risk of osteoporosis, that reduce the risk of these fragility fractures. Most commonly a bisphosphonate called Alendronate is used, however, dosing instructions are complex and only 1 in 4 people continue with the Alendronate for more than two years after starting to take it. There are many reasons for this, which include uncertainty about the benefits and safety, lack of understanding of the consequences of non- treatment and risks of, or actual side effects.

Alternative bisophosphonates are available, however, we do not know which regimens are most effective at reducing fractures, provide the best value for money and are most acceptable to patients.

The study will look at how effective different bisphosphonate regimens are compared to Alendronate at preventing fractures, whether the reduction in fracture risk can be achieved at a reasonable financial cost and to establish the acceptability of different approaches to patients.

How this study will help patients

This study will benefit patients, clinicians and the NHS by identifying:

  • which bisphosphonate treatments are most effective at reducing fractures, provide the best value for money and are most acceptable to patients
  • what patients, clinicians and researchers think are the most important research questions to inform future research in this area.

The study will be carried out in different stages:

  • Stage 1A will review of published literature on the effectiveness of and value for money provided by bisphosphonates for the prevention of fragility fractures published in 2016. The original work informed current national guidelines. We will include additional studies and data which look at treatment compliance, long-term persistence and medication safety/side-effects.
  • Stage 1B will look at existing evidence reporting patients and doctors’ views, experiences and preferences regarding different bisphosphonate regimens. This will be followed by face-to-face interviews to explore the findings from the review. Interviews will be conducted with patients, doctors and other healthcare workers/managers (including researchers) in centres that provide services for patients with osteoporosis. We will make sure the centres chosen represent a range of services and different approaches.
  • Stage 2 will use the findings from Stage 1A and 1B to identify areas of uncertainty and we will work with a nationally representative sample of patients, clinicians and researchers to generate research questions from these uncertainties. We will then hold a face-to-face national representative, multidisciplinary stakeholder event to rank these questions in order of priority for future research


Working with patients

We have worked closely with the Royal Osteoporosis Society (ROS) and the Nottingham Osteoprosis Support Group, who together have influenced the design of this application, choice of study outcomes, and who will be involved throughout the study. The ROS and two members from Nottingham Support Group have agreed to be co-applicants.

For more information

You can contact the Blastoff research team by email.





Can you help us improve our website?

Please help us to improve the Nottingham University Hospitals website by filling in this short six question survey.

Complete the website survey

*If you have filled in this survey, press the X in the top right corner